{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:19:02Z","timestamp":1790835542074,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejphar.2023.176142","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T12:04:44Z","timestamp":1697803484000},"page":"176142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Emerging therapeutic avenues in cardiac amyloidosis"],"prefix":"10.1016","volume":"960","author":[{"given":"Vaishnavi","family":"Golatkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-9300","authenticated-orcid":false,"given":"Lokesh Kumar","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.176142_bib1","unstructured":"24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejphar.2023.176142_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14797\/mdcvj.1150","article-title":"Amyloidosis of the heart and kidney","volume":"18","author":"Adrogue","year":"2022","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"10.1016\/j.ejphar.2023.176142_bib4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/00015385.2017.1335034","article-title":"Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options","volume":"72","author":"Alkhawam","year":"2017","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.ejphar.2023.176142_bib5","unstructured":"APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib6","doi-asserted-by":"crossref","first-page":"7606","DOI":"10.1039\/C4CP05563B","article-title":"On the lag phase in amyloid fibril formation","volume":"17","author":"Arosio","year":"2015","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejphar.2023.176142_bib7","first-page":"217","article-title":"Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"27","author":"Benson","year":"2020","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"10.1016\/j.ejphar.2023.176142_bib8","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176142_bib9","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC202303210","article-title":"Cardiac amyloidosis","volume":"176","author":"Bloom","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib10","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1007\/s00415-022-11276-8","article-title":"Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update","volume":"269","author":"Brannagan","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2023.176142_bib11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2023.176142_bib12","unstructured":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib13","unstructured":"A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib14","unstructured":"CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) - Full Text View - ClinicalTrials.go [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","article-title":"Cardiac amyloidosis. Two cases with digitalis sensitivity","volume":"55","author":"Cassidy","year":"1961","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib16","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/j.1742-4658.2009.06908.x","article-title":"Ribonuclease H: the enzymes in eukaryotes","volume":"276","author":"Cerritelli","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2023.176142_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ejphar.2023.176142_bib18","first-page":"52","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"10.1016\/j.ejphar.2023.176142_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.clml.2019.11.005","article-title":"Cyclophosphamide, bortezomib and dexamethasone (CyBorD) for the treatment of newly diagnosed AL amyloidosis: impact of response on survival outcomes","volume":"20","author":"Diaz-Pallares","year":"2020","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.ejphar.2023.176142_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2023.176142_bib21","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib22","unstructured":"Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-biochem-061516-045104","article-title":"Structural studies of amyloid proteins at the molecular level","volume":"86","author":"Eisenberg","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejphar.2023.176142_bib24","unstructured":"Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176142_bib26","unstructured":"First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib27","doi-asserted-by":"crossref","first-page":"15525","DOI":"10.1021\/bi051608t","article-title":"The pathway by which the tetrameric protein transthyretin dissociates","volume":"44","author":"Foss","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2023.176142_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ph12020078","article-title":"Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis","volume":"12","author":"Gales","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejphar.2023.176142_bib29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2023.176142_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2023.176142_bib31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-Human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2023.176142_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the phase 3 VITAL study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients","volume":"134","author":"Gertz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib34","doi-asserted-by":"crossref","first-page":"175","DOI":"10.17219\/acem\/142252","article-title":"Updates for the diagnosis and management of cardiac amyloidosis","volume":"31","author":"Go\u015bciniak","year":"2022","journal-title":"Adv. Clin. Exp. Med. Off. organ Wroclaw Med. Univ."},{"key":"10.1016\/j.ejphar.2023.176142_bib35","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2023.176142_bib36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00395-013-0378-5","article-title":"Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity","volume":"108","author":"Guan","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176142_bib37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/DDDT.S237252","article-title":"Review on the structures and activities of transthyretin amyloidogenesis inhibitors","volume":"14","author":"Guo","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2023.176142_bib38","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.bbmt.2019.01.007","article-title":"Induction therapy with bortezomib and dexamethasone and conditioning with high-dose melphalan and bortezomib followed by autologous stem cell transplantation for immunoglobulin light chain amyloidosis: long-term follow-up analysis","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol. blood marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.ejphar.2023.176142_bib39","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00709-020-01513-0","article-title":"Renal amyloidosis: an update on diagnosis and pathogenesis","volume":"257","author":"Gupta","year":"2020","journal-title":"Protoplasma"},{"key":"10.1016\/j.ejphar.2023.176142_bib40","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose Pharmacokinetics and Pharmacodynamics of transthyretin targeting N-acetylgalactosamine-Small interfering ribonucleic acid conjugate, vutrisiran, in Healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2023.176142_bib41","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstr\u00f6m","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176142_bib42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstr\u00f6m","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2023.176142_bib43","first-page":"178","article-title":"Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management","volume":"32","author":"Hassan","year":"2005","journal-title":"Tex. Heart Inst. J."},{"key":"10.1016\/j.ejphar.2023.176142_bib44","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3324\/haematol.2016.163246","article-title":"Lenalidomide\/melphalan\/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up","volume":"102","author":"Hegenbart","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2023.176142_bib45","unstructured":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib46","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1161\/ATVBAHA.113.301273","article-title":"Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy","volume":"33","author":"Hornstrup","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2023.176142_bib47","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-Cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2023.176142_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","article-title":"Amyloidosis in heart failure","volume":"16","author":"Ihne","year":"2019","journal-title":"Curr. Heart Fail. Rep."},{"key":"10.1016\/j.ejphar.2023.176142_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40259-023-00577-7","article-title":"RNA targeting and gene editing strategies for transthyretin amyloidosis","volume":"37","author":"Ioannou","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2023.176142_bib50","unstructured":"ION-682884 in Patients With TTR Amyloid Cardiomyopathy - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000506919","article-title":"Cardiac care of patients with cardiac amyloidosis","volume":"143","author":"Itzhaki Ben Zadok","year":"2020","journal-title":"Acta Haematol."},{"key":"10.1016\/j.ejphar.2023.176142_bib52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176142_bib53","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib54","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2023.176142_bib55","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.52300","article-title":"Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation","volume":"9","author":"Kazman","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.ejphar.2023.176142_bib57","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1038\/s41467-021-26845-0","article-title":"Dissection of the amyloid formation pathway in AL amyloidosis","volume":"12","author":"Kazman","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2023.176142_bib58","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","article-title":"Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry","volume":"129","author":"Kourelis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib59","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00392-012-0463-z","article-title":"Green tea halts progression of cardiac transthyretin amyloidosis: an observational report","volume":"101","author":"Kristen","year":"2012","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176142_bib60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000525883","article-title":"Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA Class III patients with transthyretin amyloid cardiomyopathy in the presence of death","volume":"147","author":"Li","year":"2022","journal-title":"Cardiology"},{"key":"10.1016\/j.ejphar.2023.176142_bib61","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.16198","article-title":"Establishment of brain natriuretic peptide - based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis","volume":"188","author":"Lilleness","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2023.176142_bib62","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ejphar.2023.176142_bib63","doi-asserted-by":"crossref","first-page":"14192","DOI":"10.1074\/jbc.RA118.003990","article-title":"Plasminogen activation triggers transthyretin amyloidogenesis in vitro","volume":"293","author":"Mangione","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.176142_bib64","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.currproblcancer.2016.11.004","article-title":"Light-chain cardiac amyloidosis","volume":"41","author":"Mankad","year":"2017","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ejphar.2023.176142_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2019.07.022","article-title":"Cardiac amyloidosis: an underdiagnosed\/underappreciated disease","volume":"67","author":"Manolis","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib66","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.JAA.0000697236.11386.3a","article-title":"Understanding and recognizing cardiac amyloidosis","volume":"33","author":"McVeigh","year":"2020","journal-title":"J. Am. Acad. Physician Assistants"},{"key":"10.1016\/j.ejphar.2023.176142_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137716","article-title":"Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes","volume":"10","author":"McWilliams-Koeppen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2023.176142_bib69","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2023.176142_bib70","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","article-title":"Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis","volume":"61","author":"Miller","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.176142_bib71","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaccao.2022.08.011","article-title":"Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial","volume":"4","author":"Minnema","year":"2022","journal-title":"JACC. CardioOncology"},{"key":"10.1016\/j.ejphar.2023.176142_bib72","doi-asserted-by":"crossref","first-page":"H95","DOI":"10.1152\/ajpheart.00186.2013","article-title":"Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish","volume":"305","author":"Mishra","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejphar.2023.176142_bib73","first-page":"86","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"10.1016\/j.ejphar.2023.176142_bib74","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1182\/bloodadvances.2022007781","article-title":"Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis","volume":"6","author":"Muchtar","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejphar.2023.176142_bib75","article-title":"Patisiran for advanced heart failure with hereditary transthyretin cardiac amyloidosis","author":"Nakamura","year":"2021","journal-title":"J. Cardiol. cases"},{"key":"10.1016\/j.ejphar.2023.176142_bib76","article-title":"Effectiveness of bortezomib in cardiac Al amyloidosis: a report of two cases","author":"Nigrelli","year":"2014","journal-title":"Case Rep. Med. 2014"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2023.176142_bib77","first-page":"34","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"10.1016\/j.ejphar.2023.176142_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib79","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.rdc.2018.06.004","article-title":"Secondary, AA, amyloidosis","volume":"44","author":"Papa","year":"2018","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.ejphar.2023.176142_bib80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","article-title":"The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44","volume":"119","author":"Perfetti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib81","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s42003-020-01493-0","article-title":"A serine protease secreted from Bacillus subtilis cleaves human plasma transthyretin to generate an amyloidogenic fragment","volume":"3","author":"Peterle","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ejphar.2023.176142_bib82","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.ejphar.2023.176142_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101366","article-title":"A review of cardiac amyloidosis: presentation, diagnosis, and treatment","volume":"47","author":"Pour-Ghaz","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.ejphar.2023.176142_bib84","unstructured":"A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib85","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2023.176142_bib86","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","article-title":"Long-term follow-up from a phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis","volume":"124","author":"Reece","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib87","doi-asserted-by":"crossref","first-page":"E2403","DOI":"10.1002\/humu.22619","article-title":"Online registry for mutations in hereditary amyloidosis including nomenclature recommendations","volume":"35","author":"Rowczenio","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejphar.2023.176142_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010025","article-title":"Molecular mechanisms of cardiac amyloidosis","volume":"23","author":"Saito","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.176142_bib89","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.bbmt.2015.04.001","article-title":"Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial","volume":"21","author":"Sanchorawala","year":"2015","journal-title":"Biol. blood marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"10.1016\/j.ejphar.2023.176142_bib90","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib91","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1016\/j.cell.2021.08.013","article-title":"The expanding amyloid family: structure, stability, function, and pathogenesis","volume":"184","author":"Sawaya","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2023.176142_bib92","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1006\/jmbi.2000.4415","article-title":"Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution","volume":"306","author":"Sebasti\u00e3o","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejphar.2023.176142_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.104784","article-title":"CRISPR\/Cas9 gene editing: a new hope for transthyretin amyloidosis treatment","volume":"83","author":"Shahzad","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.ejphar.2023.176142_bib94","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2023.176142_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094429","article-title":"Transthyretin misfolding, A fatal structural pathogenesis mechanism","volume":"22","author":"Si","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2023.176142_bib96","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib97","first-page":"71","article-title":"Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience","volume":"29","author":"Siddiqi","year":"2022","journal-title":"Amyloid Int. J. Exp. Clin. Investig. Off. J. Int. Soc. Amyloidosis"},{"key":"10.1016\/j.ejphar.2023.176142_bib98","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamacardio.2022.5251","article-title":"Association of tafamidis with health status in patients with ATTR cardiac amyloidosis: a post hoc analysis of the ATTR-ACT randomized clinical trial","volume":"8","author":"Sperry","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ejphar.2023.176142_bib99","doi-asserted-by":"crossref","first-page":"59","DOI":"10.14797\/mdcvj.1050","article-title":"Cardiac amyloidosis treatment","volume":"18","author":"Stern","year":"2022","journal-title":"Methodist Debakey Cardiovasc. J"},{"key":"10.1016\/j.ejphar.2023.176142_bib100","unstructured":"Study of AG10 in Amyloid Cardiomyopathy - Study Results - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib101","unstructured":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM) - [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib102","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00277-023-05090-z","article-title":"Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA","volume":"102","author":"Suzuki","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2023.176142_bib103","unstructured":"The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis - Full Text View - ClinicalTrials.gov [WWW Document], n.d."},{"key":"10.1016\/j.ejphar.2023.176142_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11082148","article-title":"Treatment of transthyretin amyloid cardiomyopathy: the current options, the future, and the challenges","volume":"11","author":"Tsch\u00f6pe","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2023.176142_bib105","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jsb.2019.06.001","article-title":"Delving into the amyloidogenic core of human leukocyte chemotactic factor 2","volume":"207","author":"Tsiolaki","year":"2019","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.ejphar.2023.176142_bib106","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139323","article-title":"Cael-101 is well-tolerated in AL amyloidosis patients receiving concomitant cyclophosphamide-bortezomib-dexamethasone (CyborD): a phase 2 dose-finding study (NCT04304144)","volume":"136","author":"Valent","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib107","article-title":"Safety and tolerability of cael-101 in combination with anti-plasma cell dyscrasia therapy in patients with AL amyloidosis: 1-year results from an open-label phase 2 trial","volume":"138","author":"Valent","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib108","doi-asserted-by":"crossref","first-page":"10127","DOI":"10.1182\/blood-2022-162597","article-title":"1-Year results from a phase 2 study to determine safety and tolerability of treating patients with light-chain (AL) amyloidosis with cael-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia","volume":"140","author":"Valent","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2023.176142_bib109","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Hear. Fail."},{"key":"10.1016\/j.ejphar.2023.176142_bib110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/phar.2639","article-title":"Advances in the treatment of transthyretin cardiac amyloidosis: current and emerging therapies","volume":"41","author":"Warner","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2023.176142_bib111","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/10600280211000351","article-title":"Transthyretin amyloid cardiomyopathy-current and future therapies","volume":"55","author":"Yadav","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2023.176142_bib112","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Hear. Fail"},{"key":"10.1016\/j.ejphar.2023.176142_bib113","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC. Basic to Transl. Sci."},{"key":"10.1016\/j.ejphar.2023.176142_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2022.100001","article-title":"Light chain amyloidosis-induced autophagy is mediated by the foxo3a\/beclin-1 pathway in cardiomyocytes","volume":"103","author":"Zhang","year":"2023","journal-title":"Lab. Invest."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923006568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299923006568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:22:46Z","timestamp":1757978566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299923006568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":114,"alternative-id":["S0014299923006568"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176142","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic avenues in cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.176142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"176142"}}